<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020860</url>
  </required_header>
  <id_info>
    <org_study_id>H-50349</org_study_id>
    <nct_id>NCT05020860</nct_id>
  </id_info>
  <brief_title>Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer</brief_title>
  <acronym>RESPONSE</acronym>
  <official_title>A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Breast Care Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Breast Care Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether clinical response (the amount a tumor shrinks&#xD;
      based on imaging or tumor measurements obtained by physical exam) predicts pathologic&#xD;
      response (the amount of tumor remaining when surgery is performed) in patients with breast&#xD;
      cancer who are receiving chemotherapy prior to surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinical Tumor Measurement vs. Pathologic Response</measure>
    <time_frame>Baseline and at surgery (after 20 weeks)</time_frame>
    <description>Clinical tumor measurements are tumor measurements obtain via imaging (mammogram or ultrasound) or by physical exam. Pathologic response is the amount of tumor remaining at the time of surgery, as determined by the pathologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response Rate in each Breast Cancer Subtype</measure>
    <time_frame>20 weeks</time_frame>
    <description>A pathologic complete response (pCR) means that there is no residual invasive cancer identified in the tissue removed at surgery. The frequency of pCR will be estimated for each breast cancer subtype (triple negative, hormone receptor positive, and HER2-positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of clinical response following 1 cycle of chemotherapy to predict pathologic complete response</measure>
    <time_frame>20 weeks</time_frame>
    <description>This aims to determine whether a 30 percent reduction in tumor size (as measured by physical exam or imaging) following one cycle of chemotherapy can predict whether a patient will have no residual invasive cancer at the time of surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in circulating tumor DNA (ctDNA) levels from baseline to surgery</measure>
    <time_frame>20 weeks</time_frame>
    <description>ctDNA is DNA from a tumor circulating in a patient's bloodstream. The goal of this is to determine whether a decrease in ctDNA levels (as measured from baseline to surgery) correlates to clinical and/or pathologic response</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasm</condition>
  <condition>Breast Cancer Female</condition>
  <condition>Breast Cancer Invasive</condition>
  <condition>Breast Cancer Stage II</condition>
  <condition>Breast Cancer Stage III</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Hormone Receptor-positive Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Triple Negative Breast Neoplasms</condition>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &gt; 5 cm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &lt; 5 cm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2-Positive Breast Cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel IV plus Trastuzumab IV plus Pertuzumab IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV administered (4 cycles total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hormone Receptor Positive Breast Cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m2 IV administered on days 1, 8, 15 of each 21-day cycle</description>
    <arm_group_label>HER2-Positive Breast Cancer</arm_group_label>
    <arm_group_label>Hormone Receptor Positive Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &lt; 5 cm)</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &gt; 5 cm)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 1.5 IV administered on days 1, 8, 15 of each 21-day cycle</description>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &gt; 5 cm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on day 1 of each 21-day cycle</description>
    <arm_group_label>HER2-Positive Breast Cancer</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on day 1 of each 21-day cycle</description>
    <arm_group_label>HER2-Positive Breast Cancer</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60 mg/m2 IV administered on day 1 of each 14-day cycle</description>
    <arm_group_label>HER2-Positive Breast Cancer</arm_group_label>
    <arm_group_label>Hormone Receptor Positive Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &lt; 5 cm)</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &gt; 5 cm)</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m2 IV administered on day 1 of each 14-day cycle</description>
    <arm_group_label>HER2-Positive Breast Cancer</arm_group_label>
    <arm_group_label>Hormone Receptor Positive Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &lt; 5 cm)</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer (for tumors &gt; 5 cm)</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be at least 18 years old, and legally able to provide informed consent. Both men&#xD;
             and women are eligible.&#xD;
&#xD;
          -  Participants must have histologically confirmed, invasive breast cancer. Tumor may be&#xD;
             triple negative (as defined by ASCO-CAP guidelines), HER2-positive (as defined by&#xD;
             ASCO-CAP guidelines), or high-risk estrogen receptor positive (as defined by ASCO-CAP&#xD;
             guidelines). High risk is defined as a tumor that meets at least two of the following&#xD;
             criteria: 1) histologic grade 3; 2) patient age less than 50 years; 3) Estrogen&#xD;
             Receptor (ER) &lt; 6/ or 4) ki-67 ≥ 30%.&#xD;
&#xD;
          -  Tumors must be at least 2 cm by clinical exam (palpation or ultrasound).&#xD;
&#xD;
          -  Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             of 0 or 1.&#xD;
&#xD;
          -  Participants must have a left ventricular ejection fraction ≥ the institutional lower&#xD;
             limit of normal, as assessed by echocardiogram or Multigated Acquisition (MUGA )scan.&#xD;
&#xD;
          -  Participants must have adequate organ function, as determined by the following&#xD;
             parameters:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1200/mm3&#xD;
&#xD;
               -  Platelets ≥ 100,000/mm3&#xD;
&#xD;
               -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ institutional upper limit of normal (ULN), unless the patient&#xD;
                  has Gilbert's disease or similar syndrome&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) ≤ 2.5 x institutional ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 1.5 x&#xD;
                  institutional ULN&#xD;
&#xD;
               -  Serum creatinine ≤ institutional ULN&#xD;
&#xD;
          -  The patient, if of childbearing potential, is willing to use effective, non-hormonal&#xD;
             contraception while on treatment.&#xD;
&#xD;
          -  Participation in a concurrent clinical trial is permitted, with principal investigator&#xD;
             approval.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have definitive clinical or radiologic evidence of Stage IV&#xD;
             disease&#xD;
&#xD;
          -  Participants must not have bilateral invasive breast cancer&#xD;
&#xD;
          -  Participants must not have inflammatory breast cancer&#xD;
&#xD;
          -  Patients must not be pregnant or lactating&#xD;
&#xD;
          -  Participants must not have a history of an excisional biopsy or lumpectomy performed&#xD;
             prior to study entry&#xD;
&#xD;
          -  Participants must not have previously received treatment with anthracyclines for any&#xD;
             malignancy.&#xD;
&#xD;
          -  Participants must not have received any treatment for currently diagnosed breast&#xD;
             cancer prior to enrollment - including endocrine therapy, chemotherapy, targeted&#xD;
             therapy, or radiation.&#xD;
&#xD;
          -  Participants must not have a history of cardiac disease that would preclude the use of&#xD;
             drugs included in these treatment regimens. This includes, but is not limited to:&#xD;
&#xD;
               -  Angina pectoris requiring the use of anti-anginal medication&#xD;
&#xD;
               -  Ventricular arrhythmias except for benign premature ventricular contractions&#xD;
&#xD;
               -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled&#xD;
                  with medication&#xD;
&#xD;
               -  Conduction abnormality requiring a pacemaker&#xD;
&#xD;
               -  Valvular disease with documented compromise in cardiac function;&#xD;
&#xD;
               -  Symptomatic pericarditis&#xD;
&#xD;
               -  Documented cardiomyopathy&#xD;
&#xD;
               -  History of documented congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction documented by elevated cardiac enzymes or persistent&#xD;
                  regional wall abnormalities, on assessment of left ventricular function.&#xD;
&#xD;
          -  Participants must not have HIV, hepatitis B, or hepatitis C infections.&#xD;
&#xD;
          -  Participants must not have a history of non-breast malignancies (with the exception of&#xD;
             in situ cancers treated only by local excision, and basal cell or squamous cell&#xD;
             carcinoma of the skin) within 5 years prior to enrollment.&#xD;
&#xD;
          -  Participants must not have any other non-malignant systemic disease that would&#xD;
             preclude treatment with any of the treatment regimens or prevent required follow-up.&#xD;
&#xD;
          -  Participants must not have any psychiatric or addictive disorders, adverse social&#xD;
             situations, or other medical conditions that, in the opinion of the investigator,&#xD;
             would preclude the patient from meeting study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mothaffar Rimawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Pavlick, BA</last_name>
    <phone>(713) 798-7814</phone>
    <email>bcc-clinicalresearch@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Pavlick, BA</last_name>
      <phone>713-798-7814</phone>
      <email>bcc-clinicalresearch@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Mothaffar Rimawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harris Health System - Smith Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Pavlick, BA</last_name>
      <phone>713-798-7814</phone>
      <email>bcc-clinicalresearch@bcm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor Breast Care Center</investigator_affiliation>
    <investigator_full_name>Mothaffar Rimawi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

